Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 29;13(8):1655.
doi: 10.3390/life13081655.

Voltage-Gated Na+ Channels in Alzheimer's Disease: Physiological Roles and Therapeutic Potential

Affiliations
Review

Voltage-Gated Na+ Channels in Alzheimer's Disease: Physiological Roles and Therapeutic Potential

Timothy J Baumgartner et al. Life (Basel). .

Abstract

Alzheimer's disease (AD) is the most common cause of dementia and is classically characterized by two major histopathological abnormalities: extracellular plaques composed of amyloid beta (Aβ) and intracellular hyperphosphorylated tau. Due to the progressive nature of the disease, it is of the utmost importance to develop disease-modifying therapeutics that tackle AD pathology in its early stages. Attenuation of hippocampal hyperactivity, one of the earliest neuronal abnormalities observed in AD brains, has emerged as a promising strategy to ameliorate cognitive deficits and abate the spread of neurotoxic species. This aberrant hyperactivity has been attributed in part to the dysfunction of voltage-gated Na+ (Nav) channels, which are central mediators of neuronal excitability. Therefore, targeting Nav channels is a promising strategy for developing disease-modifying therapeutics that can correct aberrant neuronal phenotypes in early-stage AD. This review will explore the role of Nav channels in neuronal function, their connections to AD pathology, and their potential as therapeutic targets.

Keywords: Alzheimer’s disease; excitability; hippocampus; neurodegeneration; pharmacology; plasticity; voltage-gated sodium channels.

PubMed Disclaimer

Conflict of interest statement

F.L. is the founder and president of IonTx Inc., a start-up company focusing on developing regulators of voltage-gated Na+ channels.

Figures

Figure 1
Figure 1
Schematic representation of Nav channel α- and β- subunit structure.

Similar articles

Cited by

  • Inhibition of the GSK3β/Nav1.6 complex suppresses early-stage Alzheimer's hyperexcitability.
    Baumgartner TJ, Silva-Pérez M, Haghighijoo Z, Dvorak NM, Singh AK, Goode NA, Singh J, Grebenkova BG, Marosi M, Di Re J, Koff L, Wijitrmektong W, Bala M, Liao H, Lijffijt M, Szafran AT, Bolt MJ, Mancini MA, Cuny GD, Chow DS, Limon A, Chin J, Laezza F. Baumgartner TJ, et al. Alzheimers Dement. 2025 Jul;21(7):e70507. doi: 10.1002/alz.70507. Alzheimers Dement. 2025. PMID: 40717647 Free PMC article.

References

    1. Nisbet R.M., Götz J. Amyloid-β and Tau in Alzheimer’s Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies. J. Alzheimers Dis. 2018;64:S517–S527. doi: 10.3233/JAD-179907. - DOI - PubMed
    1. U. F. O. Themes The Practical Pharmacology of Donepezil. Basicmedical Key, 21 August 2016. [(accessed on 25 July 2023)]. Available online: https://basicmedicalkey.com/the-practical-pharmacology-of-donepezil/
    1. Guo J., Wang Z., Liu R., Huang Y., Zhang N., Zhang R. Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta-Analysis. Brain Behav. 2020;10:e01831. doi: 10.1002/brb3.1831. - DOI - PMC - PubMed
    1. Padda I.S., Parmar M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. [(accessed on 25 July 2023)]. Aducanumab. Available online: http://www.ncbi.nlm.nih.gov/books/NBK573062/
    1. van Dyck C.H., Swanson C.J., Aisen P., Bateman R.J., Chen C., Gee M., Kanekiyo M., Li D., Reyderman L., Cohen S., et al. Lecanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 2023;388:9–21. doi: 10.1056/NEJMoa2212948. - DOI - PubMed

LinkOut - more resources